Earnings Call · Q3 FY2022·2022-10-27

Q3 22EPS +32.87%·Rev n/aQ2 22EPS +3.95%·Rev n/aQ1 22EPS +17.13%·Rev n/aQ4 21EPS -56.60%·Rev n/a⚠ consensus missing

GILEAD SCIENCES, INC. GILD

Jacquie Ross — Vice President, Investor Relations

Daniel O’Day — Chairman and Chief Executive Officer

Johanna Mercier — Chief Commercial Officer

Merdad Parsey — Chief Medical Officer

Andrew Dickinson — Chief Financial Officer

+12.9%1d on move date+10.5% vs SPY3d+13.0%5d+13.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more GILD calls or request research access.

More GILD calls Browse calls Request research access